FocalTherics Tumbles 17% on Offering Price and Q2 Revenue Miss
FOCL has more than doubled off its 52-week low of $1.26.
Summary
Shares fell 17% premarket after the company priced a $40M ADS offering at $4.75, a 7% discount to the prior close, and reported preliminary Q2 HIFU revenue of $12.7M-$13.2M, well below the $15.1M analyst consensus. The offering adds roughly 8.4M shares, diluting existing holders. The revenue miss, disclosed alongside the pricing, compounds the negative signal — growth is slower than the market expected. This follows yesterday's initial offering announcement and preliminary revenue range, but the pricing discount and the magnitude of the miss versus estimates are new, material negatives. The offering is expected to close August 14.
At the time of this announcement, FOCL was trading at $4.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $225.3M. The 52-week trading range was $1.26 to $6.40. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.